Leveraged & Inverse Channel This Bearish Biotech ETF Is up 16% in the Past Month By Ben HernandezOctober 12, 2021
Thematic Investing Channel The CHB ETF: China’s Burgeoning Biotech Sector By Ben HernandezMay 7, 2021
Leveraged & Inverse Channel Biotech Rose with the Virus. Now It’s Falling Behind By Ben HernandezMarch 19, 2021
Beyond Basic Beta Channel IPOs Are Back. Get In On the Action with the BBH ETF By Ben HernandezFebruary 9, 2021
Leveraged & Inverse Channel Post-Vaccine Distribution, Mergers Will Dominate Biotech Industry ETFs By Ben HernandezNovember 24, 2020
Beyond Basic Beta Channel Bullish on Biotech? The BBH ETF is Not Just a 2020 Play By Ben HernandezNovember 18, 2020
Beyond Basic Beta Channel Can’t Get Enough Biotech Exposure in Your Portfolio? By Ben HernandezOctober 29, 2020
Thematic Investing Channel China’s Quest for a Covid-19 Vaccine Could Help Boost This ETF By Ben HernandezOctober 19, 2020
Leveraged & Inverse Channel Biotech Has Been in a Steady Uptrend Even Through Covid-19 By Ben HernandezAugust 20, 2020
Innovative ETFs Channel Small Caps Can Offer Investors Big Opportunities Through 2020 By Ben HernandezAugust 3, 2020
ETF Building Blocks Channel Betting on Biotech With Utility Beyond Covid-19 By Tom LydonJuly 31, 2020
Beyond Basic Beta Channel Big Biotech Stands Tall Amid Race for Virus Vaccine By Tom LydonJuly 17, 2020
Innovative ETFs Channel Get Next-Level Biotechnology Exposure with the “GDNA” ETF By Ben HernandezJuly 6, 2020
Thematic Investing Channel There’s Still Plenty of Opportunity for Biotech Post-Coronavirus By Tom LydonJune 16, 2020
Beyond Basic Beta Channel Biotech Benefits as Companies Race to Cure Coronavirus By Tom LydonMay 26, 2020
Leveraged & Inverse Channel Traders Can Look to Biotech ETFs to For a Potential Virus Cure By Ben HernandezMay 19, 2020